2. Gene
  3. Egfr - epidermal growth factor receptor Gene

Egfr - epidermal growth factor receptor Gene

  • 基因
  • 蛋白
  • 相关产品
  • 直系同源

中文名称：表皮生长因子受体

种属: Mus musculus

同用名: Wa5; wa2; Erbb; Errp; wa-2; Errb1; 9030024J15Rik

基因 ID: 13649 | 基因类型: protein coding

关于 Egfr

Chromosome 11: 16,702,203-16,868,158 forward strand.GRCm39:CM001004.3

This gene has 5 transcripts (splice variants), 283 orthologues, 53 paralogues and is associated with 180 phenotypes. Broad expression in liver adult (RPKM 26.7), liver E18 (RPKM 8.7) and 15 other tissues.

功能概要

该基因编码的蛋白可启动表皮生长因子结合活性和表皮生长因子激活受体活性。参与细胞对氨基酸刺激的反应和成纤维细胞增殖的正调节。作用于多个过程的上游或内部，包括动物器官发育；表皮生长因子受体信号通路；和蛋白质自身磷酸化。位于几种细胞成分中，包括基底外侧质膜；内吞囊泡；和细胞质的核周区。以多种结构表达，包括消化系统；脑;外皮系统；肢;和呼吸系统。用于研究冠状病毒感染性疾病和主动脉瓣疾病。该基因的人类直系同源物与多种疾病有关，包括结直肠癌；肺非小细胞癌（多发性）；胰腺癌;前列腺癌;和肺结核。与人类 EGFR（表皮生长因子受体）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables epidermal growth factor binding activity and epidermal growth factor-activated receptor activity. Involved in cellular response to amino acid stimulus and positive regulation of fibroblast proliferation. Acts upstream of or within several processes, including animal organ development; epidermal growth factor receptor signaling pathway; and protein autophosphorylation. Located in several cellular components, including basolateral plasma membrane; endocytic vesicle; and perinuclear region of cytoplasm. Is expressed in several structures, including alimentary system; brain; integumental system; limb; and respiratory system. Used to study Coronavirus infectious disease and aortic valve disease. Human ortholog(s) of this gene implicated in several diseases, including colorectal cancer; lung non-small cell carcinoma (multiple); pancreatic cancer; prostate cancer; and pulmonary tuberculosis. Orthologous to human EGFR (epidermal growth factor receptor). [provided by Alliance of Genome Resources, Apr 2022]

Egfr 基因产物(2)

mRNA Protein Name
NM_207655.2 NP_997538.1 epidermal growth factor receptor isoform 1 precursor
NM_007912.4 NP_031938.1 epidermal growth factor receptor isoform 2 precursor

Egfr 蛋白结构

Recep_L_domain

Recep_L_domain: pfam01030 (56 - 167)

Furin-like

Furin-like: pfam00757 (183 - 334)

Recep_L_domain

Recep_L_domain: pfam01030 (361 - 480)

GF_recep_IV

GF_recep_IV: pfam14843 (504 - 635)

TM_ErbB1

TM_ErbB1: cd12093 (633 - 678)

PTKc_EGFR

PTKc_EGFR: cd05108 (705 - 1017)

  • 0
  • 200
  • 400
  • 600
  • 800
  • 1000
  • 1210 a.a.
蛋白主名 其他名称

epidermal growth factor receptor

avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

waved 2

重组 Egfr 蛋白

目录号 产品名 蛋白编号 纯度
HY-P72988 EGFR Protein, Mouse (HEK293, Fc) Q01279 (L25-S647) ≥95%
HY-P72989 EGFR Protein, Mouse (HEK293, His) Q01279 (M1-S647) ≥95%

相关产品

Approval
生物活性分子 (43)
目录号 产品名 作用方式
纯度 是否罕见病
HY-15772 Osimertinib Inhibitor 99.96% 是
HY-50895 Gefitinib Inhibitor 99.94% 是
HY-50896 Erlotinib Inhibitor 99.99% 是
HY-10261 Afatinib Inhibitor 99.93% 是
HY-138298A Trastuzumab deruxtecan Inhibitor 99.90% 否
HY-50898 Lapatinib Inhibitor 99.83% 是
HY-32721 Neratinib Inhibitor 99.59% 是
HY-P9921 Trastuzumab emtansine Inhibitor 99.74% 否
HY-16069 Tucatinib Inhibitor 99.82% 是
HY-138298 Trastuzumab deruxtecan (solution) Inhibitor 99.64% 否
HY-13272 Dacomitinib Inhibitor 99.74% 是
HY-P9985 Disitamab vedotin Inhibitor ≥99.0% 否
HY-15772A Osimertinib mesylate Inhibitor 99.95% 是
HY-135815 Mobocertinib Inhibitor 99.60% 是
HY-12008 Erlotinib Hydrochloride Inhibitor 99.93% 是
HY-104065 Pyrotinib Inhibitor 99.80% 否
HY-112870A Firmonertinib mesylate Inhibitor 99.97% 否
HY-109061 Lazertinib Inhibitor 99.07% 否
HY-112823 Almonertinib Inhibitor 99.98% 否
HY-15164A Icotinib Inhibitor 99.99% 是
HY-50895A Gefitinib hydrochloride Inhibitor 99.85% 是
HY-N0281 Daphnetin Inhibitor 99.86% 否
HY-10261A Afatinib dimaleate Inhibitor 99.88% 是
HY-19730 Olmutinib Inhibitor 99.88% 否
HY-50898A Lapatinib ditosylate Inhibitor 99.98% 是
HY-79077 Osimertinib dimesylate Inhibitor 99.96% 是
HY-104065B Pyrotinib dimaleate Inhibitor 98.56% 否
HY-15164 Icotinib Hydrochloride Inhibitor 99.81% 是
HY-112823A Almonertinib mesylate Inhibitor 99.85% 否
HY-50898B Lapatinib ditosylate monohydrate Inhibitor 99.78% 是
HY-135815A Mobocertinib succinate Inhibitor 99.61% 是
HY-118263 Dacomitinib hydrate Inhibitor 99.03% 否
HY-112823B Almonertinib hydrochloride Inhibitor 99.77% 否
HY-P9921A Trastuzumab emtansine (solution) 99.01% 否
HY-32721B Neratinib maleate Inhibitor 99.83% 是
HY-10261B (E/Z)-Afatinib Inhibitor 99.98% 否
HY-112870 Firmonertinib Inhibitor / 否
HY-10261D Afatinib oxalate Inhibitor / 否
HY-135815B Mobocertinib mesylate Inhibitor / 否
HY-50895B Gefitinib dihydrochloride Inhibitor / 否
HY-50898C Lapatinib tosylate Inhibitor / 否
HY-50895R Gefitinib (Standard) Inhibitor / 否
HY-12008A Erlotinib mesylate Inhibitor / 否
抗体抑制剂 (8)
目录号 产品名 作用方式
纯度 是否罕见病
HY-P9907 Trastuzumab Inhibitor 99.80% 否
HY-P9905 Cetuximab Inhibitor 99.70% 否
HY-P9912 Pertuzumab Inhibitor 99.80% 否
HY-P9977 Amivantamab Inhibitor 99.90% 否
HY-P99041 Panitumumab Inhibitor 98.80% 否
HY-P9968 Nimotuzumab Inhibitor 96.70% 否
HY-P99030 Margetuximab Inhibitor 98.90% 否
HY-P9964 Necitumumab Inhibitor 95.00% 否
Clinical Phase
生物活性分子 (52)
目录号 产品名 作用方式
纯度 Phase
HY-14596 Genistein Inhibitor 99.86% Phase 4
HY-50895G Gefitinib (GMP) Inhibitor / Phase 4
HY-132842 Sunvozertinib Inhibitor 99.92% Phase 3
HY-15729 Rociletinib Inhibitor 99.79% Phase 3
HY-18750 Zorifertinib Inhibitor 99.76% Phase 3
HY-13314 Tesevatinib Inhibitor 99.21% Phase 3
HY-10530 Varlitinib Inhibitor 98.03% Phase 3
HY-19816A Avitinib maleate Inhibitor ≥98.0% Phase 3
HY-19816 Avitinib Inhibitor 99.90% Phase 3
HY-138751 limertinib Inhibitor 99.12% Phase 3
HY-16069A Tucatinib hemiethanolate Inhibitor 99.97% Phase 3
HY-19803 Naquotinib mesylate Inhibitor 98.02% Phase 3
HY-15729A Rociletinib hydrobromide Inhibitor 98.04% Phase 3
HY-19729 Naquotinib Inhibitor 98.71% Phase 3
HY-144680 BLU-945 Inhibitor 99.90% Phase 2
HY-10367 Canertinib Inhibitor 99.95% Phase 2
HY-32718 Pelitinib Inhibitor 98.80% Phase 2
HY-18957 Lifirafenib Inhibitor 98.73% Phase 2
HY-112299 Zipalertinib Inhibitor 99.81% Phase 2
HY-10333 BMS-690514 Inhibitor 99.07% Phase 2
HY-10045 AEE788 Inhibitor 99.13% Phase 2
HY-136789 Tuxobertinib Inhibitor 99.94% Phase 2
HY-12872 Nazartinib Inhibitor 99.48% Phase 2
HY-12972 Mavelertinib Inhibitor 99.21% Phase 2
HY-19985 PF-06459988 Inhibitor 98.87% Phase 2
HY-10367A Canertinib dihydrochloride Inhibitor 99.12% Phase 2
HY-107367A Epertinib hydrochloride Inhibitor 98.25% Phase 2
HY-17632 Tarloxotinib bromide Inhibitor 99.26% Phase 2
HY-19909 NRC-2694 Antagonist 99.45% Phase 2
HY-107367 Epertinib Inhibitor ≥98.0% Phase 2
HY-12872A Nazartinib mesylate Inhibitor / Phase 2
HY-106204 Nelipepimut-S / Phase 2
HY-10223 CUDC-101 Inhibitor 99.19% Phase 1
HY-13501 Mubritinib Inhibitor 99.91% Phase 1
HY-15196 TAK-285 Inhibitor 99.70% Phase 1
HY-10322 Falnidamol Inhibitor 99.05% Phase 1
HY-B0794B AZ7550 Mesylate Inhibitor 99.24% Phase 1
HY-101820 Simotinib Inhibitor 99.70% Phase 1
HY-12010 BMS-599626 Hydrochloride Inhibitor 99.68% Phase 1
HY-10346A AV-412 free base Inhibitor 98.33% Phase 1
HY-111553 TAS0728 Inhibitor 99.15% Phase 1
HY-103443 HKI-357 Inhibitor 99.65% Phase 1
HY-104066 Theliatinib Inhibitor 99.77% Phase 1
HY-128778 DBPR112 Inhibitor 98.37% Phase 1
HY-139300A Epitinib succinate Inhibitor 99.01% Phase 1
HY-116437 Selatinib Inhibitor 99.83% Phase 1
HY-10346 AV-412 Inhibitor 99.17% Phase 1
HY-B0794A AZ7550 hydrochloride Inhibitor 98.66% Phase 1
HY-15732 BGB-102 Inhibitor 97.10% Phase 1
HY-104066A Theliatinib tartrate / Phase 1
HY-139300 Epitinib Inhibitor / Phase 1
HY-10251 BMS-599626 Inhibitor / Phase 1
抗体抑制剂 (30)
目录号 产品名 作用方式
纯度 Phase
HY-P9907A Trastuzumab (anti-HER2) Inhibitor 99.62% Phase 4
HY-P99854 Disitamab Inhibitor ≥95.0% Phase 4
HY-P99041A Panitumumab (anti-EGFR) Inhibitor 98.00% Phase 4
HY-P99969 Inetetamab Inhibitor 96.54% Phase 4
HY-P99275 Patritumab Inhibitor 98.94% Phase 3
HY-P99380 Zanidatamab Inhibitor 95.06% Phase 3
HY-P99849 Depatuxizumab Inhibitor 99.58% Phase 3
HY-P99155 Zalutumumab 98.26% Phase 3
HY-P99676 Izalontamab Inhibitor 99.03% Phase 3
HY-P99455 Bafisontamab Inhibitor 96.00% Phase 3
HY-P99437 Anbenitamab Inhibitor 99.22% Phase 3
HY-P99831 Coprelotamab / Phase 3
HY-P99630 Gancotamab Inhibitor / Phase 3
HY-P99268 Seribantumab Inhibitor ≥95.0% Phase 2
HY-P99507 Zenocutuzumab Inhibitor 99.20% Phase 2
HY-P99406 Petosemtamab Degrader 95.00% Phase 2
HY-P9969 Matuzumab 98.12% Phase 2
HY-P99936 Elgemtumab Inhibitor 96.80% Phase 2
HY-P99618 Fidasimtamab Inhibitor 95.00% Phase 2
HY-P99216 Ponezumab Inhibitor 99.39% Phase 2
HY-P99866 Duligotuzumab 97.93% Phase 2
HY-P99715 Losatuxizumab Inhibitor 95.00% Phase 2
HY-P990049 Becotatug Inhibitor 98.44% Phase 2
HY-P99296 Intetumumab Inhibitor 99.24% Phase 2
HY-P99605 Cinrebafusp alfa Inhibitor 98.53% Phase 2
HY-P99295 Imgatuzumab Inhibitor / Phase 2
HY-P99628 Futuximab Inhibitor / Phase 2
HY-P99672 Istiratumab Inhibitor / Phase 2
HY-P99304 Lumretuzumab Inhibitor 95.00% Phase 1
HY-P99461 Barecetamab Inhibitor 97.96% Phase 1
Pre-clinical Phase
生物活性分子 (446)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-12000 AG490 Inhibitor 99.97% 否
HY-13524 AG-1478 Inhibitor 99.22% 否
HY-101084 NSC 228155 Activator ≥98.0% 否
HY-13050 Sapitinib Inhibitor 99.93% 否
HY-13595 Chrysophanol Inhibitor 99.77% 否
HY-100848 TX1-85-1 Inhibitor 98.04% 否
HY-16558 Butein Inhibitor 99.95% 否
HY-14346 PD153035 Inhibitor 98.83% 否
HY-N0280 Corosolic acid 99.23% 否
HY-123921 Gefitinib-based PROTAC 3 Inhibitor 99.98% 否
HY-N2409 Delphinidin chloride Inhibitor ≥98.0% 否
HY-100213 EAI045 Inhibitor 99.08% 否
HY-15644 Tyrphostin 23 Inhibitor 99.43% 否
HY-129550 BI-4020 Inhibitor 99.28% 否
HY-B0793 AZ-5104 Inhibitor 99.70% 否
HY-13896 PD168393 Inhibitor 98.60% 否
HY-18609 PD158780 Inhibitor 99.56% 否
HY-14674 CP-724714 Inhibitor 98.53% 否
HY-111138 CZC-8004 Inhibitor 99.81% 否
HY-W016412 Coenzyme Q0 Inhibitor 99.88% 否
HY-12026 WZ4002 Inhibitor 99.76% 否
HY-20878 Tyrphostin AG 879 Inhibitor 99.85% 否
HY-15844 AG-825 Inhibitor 98.02% 否
HY-15730 Poziotinib Inhibitor 99.96% 否
HY-N2450 Sulforaphene Inhibitor 99.80% 否
HY-147183B JBJ-09-063 hydrochloride Inhibitor 99.37% 否
HY-13427 Allitinib tosylate Inhibitor 99.83% 否
HY-13895 WHI-P154 Inhibitor 99.39% 否
HY-12001 WZ-3146 Inhibitor 99.63% 否
HY-109189 Rezivertinib Inhibitor 99.43% 否
HY-P1845A PACAP-38 (31-38), human, mouse, rat TFA Inducer 99.59% 否
HY-135805A (Rac)-JBJ-04-125-02 Inhibitor ≥95.0% 否
HY-150024 BI-4142 Inhibitor 98.39% 否
HY-144880 SC209 Inhibitor 99.52% 否
HY-N1166 Tephrosin ≥97.0% 否
HY-14596R Genistein (Standard) Inhibitor 99.31% 否
HY-P1845 PACAP-38 (31-38), human, mouse, rat Inducer 99.98% 否
HY-10325 CL-387785 Inhibitor 98.05% 否
HY-78869 Mutated EGFR-IN-1 Inhibitor 99.84% 否
HY-19815 Olafertinib Inhibitor 99.51% 否
HY-147183A JBJ-09-063 TFA Inhibitor 99.64% 否
HY-108052 Delphinidin 3-glucoside chloride Inhibitor 99.83% 否
HY-10531 ARRY-380 analog Inhibitor 99.19% 否
HY-14596S Genistein-d4 Inhibitor 98.81% 否
HY-15769 WHI-P180 Inhibitor 99.62% 否
HY-128862 EGFR-IN-7 Inhibitor 99.76% 否
HY-107364 MTX-211 Inhibitor ≥98.0% 否
HY-147941A MS9427 TFA Degrader 99.01% 否
HY-137191 CH7233163 Inhibitor 99.61% 否
HY-101219 VEGFR-IN-1 Inhibitor 98.42% 否
HY-123578 NSC689857 Inhibitor 99.65% 否
HY-43533 Tarlox-TKI Inhibitor 97.03% 否
HY-100434 PD-161570 Inhibitor 99.04% 否
HY-112411 PD 174265 Inhibitor 98.72% 否
HY-12029 WZ8040 Inhibitor 99.22% 否
HY-134877 BAY 2476568 Inhibitor 98.05% 否
HY-150023 BI-1622 Inhibitor 98.97% 否
HY-137433 Befotertinib Inhibitor 99.96% 否
HY-136430 JCN037 Inhibitor 99.76% 否
HY-142283AS Dosimertinib mesylate Inhibitor 99.44% 否
HY-101450 PF-6274484 Inhibitor 98.41% 否
HY-153268 BDTX-1535 Inhibitor 99.03% 否
HY-100499 Tyrphostin AG 528 Inhibitor ≥98.0% 否
HY-101960A Tyrphostin A51 Inhibitor ≥99.0% 否
HY-17499 EGFR-IN-12 Inhibitor 99.40% 否
HY-15801 HG-14-10-04 Inhibitor 99.09% 否
HY-103440 EGFR/ErbB-2/ErbB-4 inhibitor-3 Inhibitor 98.19% 否
HY-132842A (S)-Sunvozertinib Inhibitor 99.14% 否
HY-139920 Oritinib Inhibitor 99.18% 否
HY-138627A AST5902 trimesylate Inhibitor 99.87% 否
HY-N2510 Myristicin Inhibitor 99.89% 否
HY-124813 PDZ1i Inhibitor 99.29% 否
HY-112293 GW2974 99.54% 否
HY-103566 LY456236 Inhibitor 99.81% 否
HY-101042 AG-494 Inhibitor 99.31% 否
HY-B1394 Khellin Inhibitor 99.89% 否
HY-124674A CCT365623 hydrochloride Inhibitor 98.11% 否
HY-117155 PKI-166 Inhibitor 99.58% 否
HY-N0211 Cyasterone Inhibitor 99.58% 否
HY-155537 YK-029A Inhibitor 99.50% 否
HY-112420 EGFR/ErbB-2/ErbB-4 inhibitor-2 Inhibitor 99.69% 否
HY-12008S Erlotinib-d6 hydrochloride Inhibitor 98.13% 否
HY-153110A Larotinib mesylate hydrate Inhibitor 98.66% 否
HY-141481 DP-C-4 Inhibitor 99.72% 否
HY-100962 (E)-AG 99 Inhibitor 98.36% 否
HY-41404 Piperonylic acid 99.86% 否
HY-120590 Ruserontinib Inhibitor 99.82% 否
HY-101429 RG13022 Inhibitor ≥95.0% 否
HY-107459 (E/Z)-AG490 Inhibitor 99.97% 否
HY-150611 EGFR-IN-70 Inhibitor 99.16% 否
HY-18963 Lavendustin A Inhibitor 98.02% 否
HY-112345 PD-089828 Inhibitor 98.07% 否
HY-N4201 β-Hydroxyisovalerylshikonin Inhibitor 99.83% 否
HY-19617B EGFR-IN-1 TFA Inhibitor 99.38% 否
HY-101426 RG14620 Inhibitor 98.09% 否
HY-N6577 Astragaloside VI 99.95% 否
HY-123952 RTC-5 Inhibitor 99.89% 否
HY-12013 PD153035 Hydrochloride Inhibitor 98.78% 否
HY-15772S Osimertinib-d6 Inhibitor 99.97% 否
HY-18603 FIIN-3 Inhibitor 99.66% 否
HY-119944 JND3229 Inhibitor 99.78% 否
HY-147413 Unecritinib Inhibitor 98.83% 否
HY-157229 STX-721 Inhibitor 98.25% 否
HY-100214 EAI001 Inhibitor 99.88% 否
HY-147219A SIAIS164018 hydrochloride Inhibitor 99.84% 否
HY-155079 DZD1516 98.31% 否
HY-W013857 Lavendustin C Inhibitor 98.32% 否
HY-138072 EMI1 Inhibitor 99.78% 否
HY-P1855 HER2/neu (654-662) GP2 98.04% 否
HY-150610 EGFR-IN-69 Inhibitor 99.58% 否
HY-135805B (Rac)-JBJ-04-125-02 acetate 96.58% 否
HY-15772S1 Osimertinib-13C,d3 99.14% 否
HY-P5314 OK2 Inhibitor 95.95% 否
HY-144304 PROTAC EGFR degrader 2 Inhibitor 95.61% 否
HY-13984 Mutant EGFR inhibitor Inhibitor 99.51% 否
HY-103442 CGP52411 Inhibitor 99.82% 否
HY-10261S Afatinib-d6 Inhibitor ≥99.0% 否
HY-153111 EGFR/HER2-IN-9 Inhibitor 98.73% 否
HY-13897 CNX-2006 Inhibitor 98.42% 否
HY-U00002 ZD-4190 Inhibitor 98.08% 否
HY-101041 (E)-AG 556 Inhibitor 99.92% 否
HY-50895S Gefitinib-d8 Inhibitor 98.42% 否
HY-126320 EGFR-IN-8 Inhibitor 98.01% 否
HY-145960 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Agonist 99.39% 否
HY-130608 Mutated EGFR-IN-3 Inhibitor / 否
HY-147183 JBJ-09-063 Inhibitor / 否
HY-147941 MS9427 Degrader 95.29% 否
HY-147219 SIAIS164018 Inhibitor / 否
HY-19617A EGFR-IN-1 hydrochloride Inhibitor / 否
HY-19617 EGFR-IN-1 Inhibitor / 否
HY-130616 EGFR-IN-11 Inhibitor 99.30% 否
HY-115716 EGFR-IN-17 Inhibitor 98.42% 否
HY-135805 JBJ-04-125-02 Inhibitor / 否
HY-133780 Afatinib impurity 11 Inhibitor 99.10% 否
HY-50895S1 Gefitinib-d6 Inhibitor ≥98.0% 否
HY-155358 Os30 Inhibitor 98.34% 否
HY-15336 AG 555 Inhibitor ≥98.0% 否
HY-118532 Tyrphostin AG30 Inhibitor 99.70% 否
HY-B0794 AZ7550 Inhibitor / 否
HY-13272S2 Dacomitinib-d10 dihydrochloride Inhibitor ≥95.0% 否
HY-12872B Nazartinib S-enantiomer 98.66% 否
HY-149636 Multi-target kinase inhibitor 2 Inhibitor 99.82% 否
HY-100923 H-9 Dihydrochloride Inhibitor 98.98% 否
HY-126319 SU5204 Inhibitor 99.46% 否
HY-103439 GW583340 dihydrochloride Inhibitor / 否
HY-144677 pan-HER-IN-2 Inhibitor 98.10% 否
HY-131864 SJF-1528 Degrader / 否
HY-12806 AG1557 Inhibitor 99.63% 否
HY-P2503 EGFR Protein Tyrosine Kinase Substrate 99.05% 否
HY-50896S Erlotinib-d6 Inhibitor / 否
HY-108484 PP 3 Inhibitor 99.79% 否
HY-101007A (+)-Tyrphostin B44 Inhibitor 97.01% 否
HY-157480 EGFR/AURKB-IN-1 Inhibitor / 否
HY-101006 Methyl 2,5-dihydroxycinnamate Inhibitor 99.70% 否
HY-111452 EGFR-IN-85 Inhibitor / 否
HY-103441 JNJ28871063 hydrochloride Inhibitor / 否
HY-157413 YS-67 Inhibitor 99.41% 否
HY-158149 T-1-PMPA Inhibitor 99.70% 否
HY-147942 MS9449 / 否
HY-113599 Isoprocurcumenol Activator 95.41% 否
HY-131865 SJF-1521 Degrader 99.20% 否
HY-101756 SDZ281-977 98.00% 否
HY-138751A limertinib diTFA Inhibitor ≥98.0% 否
HY-18750A Zorifertinib hydrochloride Inhibitor / 否
HY-142283 Dosimertinib Inhibitor / 否
HY-19981B Derazantinib dihydrochloride Inhibitor / 否
HY-135914 JBJ-02-112-05 Inhibitor / 否
HY-163428 ZN-A-1041 Inhibitor / 否
HY-128860 Mutated EGFR-IN-2 Inhibitor / 否
HY-163354 EGFR-IN-103 Inhibitor / 否
HY-143734 HER2-IN-6 / 否
HY-132883 EGFR/CSC-IN-1 Inhibitor / 否
HY-131067 EMI56 Inhibitor 99.72% 否
HY-115951 EGFR/HER2-IN-2 Inhibitor / 否
HY-153110 Larotinib Inhibitor / 否
HY-10407G SU 5402 (GMP) Inhibitor / 否
HY-138627 AST5902 Inhibitor / 否
HY-125841 EGFR mutant-IN-1 Inhibitor / 否
HY-139920A Oritinib mesylate Inhibitor / 否
HY-10530A Varlitinib tosylate Inhibitor / 否
HY-147303 Sacibertinib Inhibitor / 否
HY-131066 EMI48 Inhibitor 99.02% 否
HY-138746 EGFR-IN-15 Inhibitor / 否
HY-144048 EGFR-IN-31 / 否
HY-155285 YS-363 Inhibitor / 否
HY-143729 EGFR-IN-29 Inhibitor / 否
HY-162483 EGFR kinase inhibitor 6 Inhibitor / 否
HY-13272S3 Dacomitinib-d10 Inhibitor / 否
HY-156284 EGFR-IN-89 Inhibitor / 否
HY-100636A Gefitinib N-oxide hydrochloride Inhibitor / 否
HY-158018 EGFR-TK-IN-2 Inhibitor / 否
HY-162482 EGFR kinase inhibitor 5 Inhibitor / 否
HY-158829 SSOe26 sodium / 否
HY-112405 BPIQ-I Inhibitor / 否
HY-153557A HER2-IN-14 Inhibitor / 否
HY-10261AS Afatinib-d6 dimaleate Inhibitor / 否
HY-157402 Topoisomerase II/EGFR-IN-1 / 否
HY-163632 EGFR-IN-112 Inhibitor / 否
HY-100064S1 O-Desmethyl gefitinib-d6 Inhibitor / 否
HY-161536 PROTAC EGFR degrader 9 Inhibitor / 否
HY-147741 DPPY Inhibitor / 否
HY-143246 EGFR kinase inhibitor 1 Inhibitor / 否
HY-158828 SSO111 sodium / 否
HY-158153 EGFR-IN-108 Inhibitor / 否
HY-157399 EGFR/HER2-IN-10 Inhibitor / 否
HY-145823 EGFR-IN-42 Inhibitor / 否
HY-144050 EGFR-IN-33 Inhibitor / 否
HY-152144 EGFR-IN-75 Inhibitor / 否
HY-146239 EGFR/HER2/TS-IN-2 Inhibitor / 否
HY-149556 MTX-241F Inhibitor / 否
HY-149824 EGFR T790M/L858R-IN-2 Inhibitor 99.66% 否
HY-149517 EGFR/BRAFV600E-IN-2 Inhibitor / 否
HY-143323 HER2-IN-9 Inhibitor / 否
HY-103437 EGFR-IN-80 Inhibitor / 否
HY-163402 EGFR-IN-108 chloride Inhibitor / 否
HY-163434 PRMT5/EGFR-IN-1 Inhibitor / 否
HY-148460 Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine Inhibitor / 否
HY-137028 2′-Thioadenosine Inhibitor / 否
HY-158310 SOS1/EGFR-IN-1 Inhibitor / 否
HY-158154 EGFR-IN-110 Inhibitor / 否
HY-156912 Tyrosine kinase-IN-7 Inhibitor 99.25% 否
HY-155227 ALK/EGFR-IN-1 Inhibitor / 否
HY-113549 Erbstatin Inhibitor / 否
HY-157994 EGFR WT/T790M-IN-2 Inhibitor / 否
HY-143337 EGFR-IN-47 Inhibitor / 否
HY-150781 EGFR-IN-71 Inhibitor / 否
HY-141486A PROTAC PARP/EGFR ligand 1 / 否
HY-146474 EGFR-IN-54 Inhibitor / 否
HY-157432 EGFR-IN-97 Inhibitor / 否
HY-147796 EGFR/HER2/CDK9-IN-1 Inhibitor / 否
HY-110333 BMS-599626 dihydrochloride Inhibitor / 否
HY-151882 EGFR-IN-73 Inhibitor / 否
HY-146471 EGFR-IN-51 Inhibitor / 否
HY-158178 EGFR T790M/L858R-IN-7 Inhibitor / 否
HY-144605 PROTAC EGFR degrader 3 Inhibitor 97.39% 否
HY-B0794S AZ7550-d5 Inhibitor / 否
HY-144760 EGFR-IN-3 Inducer / 否
HY-143733 HER2-IN-5 Inhibitor / 否
HY-157324 EGFR-IN-94 Inhibitor / 否
HY-131710 PDE5-IN-3 Inhibitor / 否
HY-142681 EGFR-IN-28 Inhibitor / 否
HY-156114 EGFR/CDK2-IN-2 Inhibitor / 否
HY-152098 HX103 Inhibitor / 否
HY-155736 MAPK-IN-2 Inhibitor / 否
HY-161136 EGFR/STAT3-IN-1 Inhibitor / 否
HY-153744 JGK-068S Inhibitor / 否
HY-P5258 Oligopeptide-41 Inducer / 否
HY-142283BS N-Desmethyl dosimertinib-d5 / 否
HY-118998 TX2-121-1 Inhibitor / 否
HY-162254 EGFR/ACK1-IN-1 Inhibitor / 否
HY-157581 MS39 Degrader / 否
HY-139884 EGFR-IN-18 Inhibitor / 否
HY-158016 Antiproliferative agent-49 Inhibitor / 否
HY-162300 EGFR kinase inhibitor 4 Inhibitor / 否
HY-147967 EGFR-IN-63 Inhibitor / 否
HY-147826 EGFR-IN-60 Inhibitor / 否
HY-50898S3 Lapatinib-d4-1 Inhibitor / 否
HY-W174279 Tyrphostin 8 Inhibitor ≥98.0% 否
HY-114535 Jaceidin Inhibitor / 否
HY-149518 EGFR/BRAFV600E-IN-3 Inhibitor / 否
HY-144676 pan-HER-IN-1 Inhibitor / 否
HY-142680 EGFR-IN-23 Inhibitor / 否
HY-108931 AG 1406 Inhibitor 99.03% 否
HY-147996 EGFR-IN-67 Inhibitor / 否
HY-149695 EGFR-IN-91 Inhibitor / 否
HY-163094 EGFR-IN-95 Inhibitor / 否
HY-144054 EGFR-IN-37 Inhibitor / 否
HY-144052 EGFR-IN-35 Inhibitor / 否
HY-157526 EGFR-TK-IN-1 Inhibitor / 否
HY-142678 EGFR-IN-21 Inhibitor / 否
HY-B0793S1 AZ-5104-d2 Inhibitor / 否
HY-147994 EGFR/HER2-IN-5 Inhibitor / 否
HY-101959 Tyrphostin AG213 Inhibitor / 否
HY-110039 BIBX 1382 dihydrochloride Inhibitor / 否
HY-100064S O-Desmethyl gefitinib-d8 Inhibitor 99.84% 否
HY-161030 EGFR-IN-92 Inhibitor / 否
HY-160564 ZNL-0056 Inhibitor / 否
HY-156457 EGFR-IN-90 Inhibitor / 否
HY-151161 EGFR/HER2-IN-8 Inhibitor / 否
HY-161031 EGFR-IN-93 Inhibitor / 否
HY-101522 CHMFL-EGFR-202 Inhibitor 99.75% 否
HY-100064 O-Desmethyl gefitinib Inhibitor 99.40% 否
HY-158177 EGFR T790M/L858R-IN-6 Inhibitor / 否
HY-142512 EGFR-IN-24 Inhibitor / 否
HY-151156 EGFR/HER2-IN-6 Inhibitor / 否
HY-146782 EGFR-IN-49 Inhibitor / 否
HY-146423 PROTAC EGFR degrader 6 Inhibitor / 否
HY-101960 (Z)-Tyrphostin A51 Inhibitor / 否
HY-146349 PROTAC EGFR degrader 4 Inhibitor / 否
HY-161269 EGFR-IN-101 Inhibitor / 否
HY-151981 EGFR-IN-74 Inhibitor / 否
HY-161408 GePhos1 / 否
HY-162062 EGFR WT/T790M/L858R-IN-1 Inhibitor / 否
HY-163371 EGFR WT/T790M-IN-1 Inhibitor / 否
HY-163417 HER2-IN-15 Inhibitor / 否
HY-13595R Chrysophanol (Standard) Inhibitor / 否
HY-161618 MJ04 Inhibitor / 否
HY-147992 EGFR/HER2-IN-4 Inhibitor / 否
HY-155969 EGFR-IN-83 Inhibitor / 否
HY-155200 EGFR-IN-84 Inhibitor / 否
HY-142283CS N-Methyl-dosimertinib-d5 / 否
HY-157398 EGFR T790M/L858R-IN-3 Inhibitor / 否
HY-137786 EGFR-IN-16 Inhibitor / 否
HY-161319 EGFR-IN-104 Inhibitor / 否
HY-144055 EGFR-IN-38 Inhibitor / 否
HY-144056 EGFR-IN-39 Inhibitor / 否
HY-13524A AG-1478 hydrochloride Inhibitor / 否
HY-W423595 BEBT-109 Inhibitor / 否
HY-10261E (R)-Afatinib Inhibitor / 否
HY-147798 EGFR/HER2/CDK9-IN-3 Inhibitor / 否
HY-156116 EGFR/CDK2-IN-4 Inhibitor / 否
HY-158176 EGFR T790M/L858R-IN-5 Inhibitor / 否
HY-149846 SIQ17 Inhibitor / 否
HY-156741 EGFR-IN-87 Inhibitor / 否
HY-143901 EGFR-IN-40 Inhibitor / 否
HY-161537 EGFR ligand-9 Inhibitor / 否
HY-146210 EGFR-IN-50 Inhibitor / 否
HY-150782 UNC-CA359 Inhibitor / 否
HY-147802 EGFR-IN-59 Inhibitor / 否
HY-161320 EGFR-IN-105 Inhibitor / 否
HY-146136 EGFR-IN-56 Inhibitor / 否
HY-144097 HER2-IN-8 Inhibitor / 否
HY-162148 HNPMI Inhibitor / 否
HY-144444 NSC381467 Inhibitor / 否
HY-151159 DHFR-IN-4 Inhibitor / 否
HY-19985A (3S,4S)-PF-06459988 99.85% 否
HY-163418 HER2-IN-17 Inhibitor / 否
HY-146422 PROTAC EGFR degrader 5 Inhibitor / 否
HY-149407 Multi-kinase-IN-4 Inhibitor / 否
HY-161146 EGFR-IN-100 Inhibitor / 否
HY-153557 HER2-IN-13 Inhibitor / 否
HY-127067 Yuanhuadin Inhibitor / 否
HY-162099 VEGFR-IN-4 Inhibitor / 否
HY-149889 EGFR-IN-78 Inhibitor / 否
HY-144049 EGFR-IN-32 Inhibitor / 否
HY-147997 EGFR-IN-68 Inhibitor / 否
HY-142519 EGFR-IN-27 Inhibitor / 否
HY-162332 EGFR-PK/JNK-2-IN-1 Inhibitor / 否
HY-100636 Gefitinib N-oxide Inhibitor / 否
HY-147995 EGFR-IN-64 Inhibitor / 否
HY-145867 EGFR-IN-45 Inhibitor / 否
HY-145824 EGFR-IN-43 Inhibitor / 否
HY-163453 HER2-IN-19 Inhibitor / 否
HY-151158 EGFR/HER2-IN-7 Inhibitor / 否
HY-161275 BI-4732 Inhibitor / 否
HY-142517 EGFR-IN-25 Inhibitor / 否
HY-160613 EGFR/HER2-IN-11 Inhibitor / 否
HY-146228 HSP90-IN-13 Inhibitor / 否
HY-144445 NSC114126 Inhibitor / 否
HY-153901 PROTAC EGFR degrader 8 Inhibitor / 否
HY-162323 EGFR-IN-106 Inhibitor / 否
HY-151377 RET-IN-19 Inhibitor / 否
HY-143874 HER2-IN-7 Inhibitor / 否
HY-162360 EGFR-IN-109 Inhibitor / 否
HY-163419 HER2-IN-18 Inhibitor / 否
HY-100663 Gefitinib impurity 2 99.56% 否
HY-18213 EGFR-IN-9 Inhibitor 98.84% 否
HY-146238 EGFR/HER2/TS-IN-1 Inhibitor / 否
HY-115933 EGFR/BRAF-IN-1 Inhibitor / 否
HY-144044 EGFR-IN-30 Inhibitor / 否
HY-156470 Multi-kinase-IN-6 Inhibitor / 否
HY-160068 2-2(t) aptamer sodium Chemical / 否
HY-147858 PROTAC EGFR degrader 7 Inhibitor / 否
HY-147825 EGFR/BRAFV600E-IN-1 Inhibitor / 否
HY-157166 EGFR kinase inhibitor 2 Inhibitor / 否
HY-144441 NSC81111 Inhibitor / 否
HY-108016 Peruvoside Inhibitor / 否
HY-145844 EGFR-IN-44 Inhibitor / 否
HY-158175 EGFR T790M/L858R-IN-4 Inhibitor / 否
HY-144794 EGFR-IN-46 Inhibitor / 否
HY-101958 Tyrphostin 25 Inhibitor / 否
HY-P2548 pp60 (v-SRC) Autophosphorylation Site, Phosphorylated / 否
HY-161602 EGFR/HER2-IN-13 Inhibitor / 否
HY-161126 EGFR-IN-98 Inhibitor / 否
HY-141640 MS154 Inhibitor / 否
HY-147860 EGFR-IN-61 Inhibitor / 否
HY-146170 Anticancer agent 69 Inhibitor / 否
HY-146473 EGFR-IN-53 Inhibitor / 否
HY-155074 EGFR-IN-79 Inhibitor / 否
HY-149530 EGFR-IN-86 Inhibitor / 否
HY-155005 EGFR mutant-IN-2 Inhibitor / 否
HY-146472 EGFR-IN-52 Inhibitor / 否
HY-149632 EGFR/HER2/DHFR-IN-2 Inhibitor / 否
HY-149275 PKM2/PDK1-IN-1 Inhibitor / 否
HY-12008S1 Erlotinib-13C6 hydrochloride / 否
HY-160682 EGFR/HER2-IN-12 Inhibitor / 否
HY-155118 EGFR-IN-81 Inhibitor / 否
HY-P1085 Epidermal Growth Factor Receptor Peptide (985-996) Chemical / 否
HY-143445 EGFR-IN-48 Inhibitor / 否
HY-110328 PKI-166 hydrochloride Inhibitor / 否
HY-161145 EGFR/microtubule-IN-1 Inhibitor / 否
HY-112474 Tyrphostin AG 112 Inhibitor 98.55% 否
HY-163420 HER2-IN-16 Inhibitor / 否
HY-P4082 ErbB-2-binding peptide / 否
HY-121828 TX-1123 Inhibitor / 否
HY-151154 EGFR/HER2/DHFR-IN-1 Inhibitor / 否
HY-50896S1 Erlotinib-13C6 Inhibitor / 否
HY-132259 Depatuxizumab mafodotin / 否
HY-162299 EGFR kinase inhibitor 3 Inhibitor / 否
HY-161603 EGFR/HER2-IN-14 Inhibitor / 否
HY-146132 EGFR-IN-55 Inhibitor / 否
HY-149401 EGFR-IN-82 Inhibitor / 否
HY-50898S Lapatinib-d4 Inhibitor 99.02% 否
HY-50898S2 Lapatinib-d5 Inhibitor / 否
HY-155178 Antiproliferative agent-34 Inhibitor / 否
HY-152019 EGFR/C797S-IN-1 Inhibitor / 否
HY-161045 T-1-DOCA Inhibitor / 否
HY-150905 EGFR ligand-2 Inhibitor / 否
HY-P2673 Lys-Arg-Thr-Leu-Arg-Arg / 否
HY-149633 EGFR/HER2/DHFR-IN-3 Inhibitor / 否
HY-10261S1 Afatinib-d4 Inhibitor / 否
HY-163377 AZ5385 Inhibitor / 否
HY-101820A Simotinib hydrochloride Inhibitor / 否
HY-151162 HER2-IN-12 Inhibitor / 否
HY-156115 EGFR/CDK2-IN-3 Inhibitor / 否
HY-156639 EGFR/ErbB-2 inhibitor-1 Inhibitor / 否
HY-146138 EGFR-IN-57 Inhibitor / 否
HY-115952 EGFR/HER2-IN-3 Inhibitor / 否
HY-15268 PP487 Inhibitor / 否
HY-146154 EGFR-IN-58 Inhibitor / 否
HY-161067 EGFR-IN-96 Inhibitor / 否
HY-163006 EGFR/c-Met-IN-1 Inhibitor / 否
HY-149344 Anticancer agent 133 Inhibitor / 否
HY-W008914 (E/Z)-CP-724714 Inhibitor / 否
HY-50898S1 Lapatinib-d7 dihydrochloride Inhibitor / 否
HY-147862 EGFR-IN-62 Inhibitor / 否
HY-144053 EGFR-IN-36 Inhibitor / 否
HY-156033 EGFR-IN-88 Inhibitor / 否
HY-157912 EGFR-IN-102 Inhibitor / 否
HY-144051 EGFR-IN-34 Inhibitor / 否
HY-142679 EGFR-IN-22 Inhibitor / 否
HY-151573 EGFR/CDK2-IN-1 Inhibitor / 否
HY-147797 EGFR/HER2/CDK9-IN-2 Inhibitor / 否
HY-15769A WHI-P180 hydrochloride Inhibitor / 否
HY-50895S2 Gefitinib-d3 Inhibitor / 否
HY-18957B Lifirafenib maleate Inhibitor / 否
HY-163396 EGFR-IN-107 Inhibitor / 否
HY-123766 EGFR-IN-99 Inhibitor / 否
HY-157579 MS154N / 否
HY-137433A Befotertinib mesylate Inhibitor / 否
HY-117523 (Z)-RG-13022 Inhibitor / 否
HY-32721S Neratinib-d6 Inhibitor / 否
HY-15375 Allitinib Inhibitor / 否
HY-146262 LDC0496 Inhibitor / 否
HY-100520 EGFR-IN-2 Inhibitor / 否
HY-111415 EGFR-IN-5 Inhibitor / 否
抗体抑制剂 (7)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P9912A Pertuzumab (PBS) Inhibitor 99.10% 否
HY-P99684 Laprituximab Inhibitor 95.00% 否
HY-P99888 Pimurutamab / 否
HY-P99324 Tomuzotuximab Inhibitor / 否
HY-P99892 Serclutamab 99.97% 否
HY-P990055 Nezutatug Inhibitor / 否
HY-P99558 Timigutuzumab Inhibitor / 否

直系同源

种属 基因名 来源 基因 ID
Homo sapiens Egfr NCBI NCBI:1956
Canis familiaris Egfr NCBI NCBI:404306
Macaca fascicularis Egfr NCBI NCBI:102138724
Rattus norvegicus Egfr NCBI NCBI:24329
Macaca mulatta Egfr NCBI NCBI:613027
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z